Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose pharmacokinetics of belzutifan (MK-6482) in healthy Japanese female participants
jRCT2031220024Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of belzutifan in renal cell carcinoma (RCC) (4 arms), sponsored by Merck & Co. Primary endpoints: Cmax, Tmax and 5 more. Started Apr 2022; status: completed.
02
Drugs
belzutifan
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on jRCT2031220024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220024.